20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.…
20/20 BioLabs Reports Third Quarter 2026 Financial Results and Recent Business Updates
20/20 Biolabs (NASDAQ: AIDX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 4 employees.
The shares were at 0.1571 USD on 20 November 2026. Its 52-week range is 0.1556 USD to 50.00 USD, and it trades at the bottom of that range.
Its market capitalisation is 2.20M USD.
20/20 Biolabs reports an operating margin of -249.2% and revenue down 9.0% year over year.
It holds more cash than debt, a net cash position of 3.11M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health.